Virus therapy takes on Hard-to-Treat cancers

NCT ID NCT05427487

Recruiting now Disease control Sponsor: ImmVirx Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the virus can shrink tumours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IVX037 (a virus that targets and kills cancer cells) and sintilimab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumours that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 70 participants, so safety and dosing are still being figured out. The virus may not shrink tumours or could cause side effects like flu-like symptoms or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GASTRIC CANCER OVARIAN CANCER

Contacts and locations

Locations

Melbourne Site
RECRUITING

Melbourne, Victoria, 3000, Australia
South Australia site
RECRUITING

Adelaide, South Australia, 5000, Australia
Sydney site
RECRUITING

Sydney, New South Wales, 2000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.